Editas medicine stock price.

Moreover, the 36-month beta value for EDIT is 1.79. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 8 as “hold,” and 1 as “sell.” The average price recommended by analysts for Editas Medicine Inc (EDIT) is $13.93, which is $5.41 above the current market price.Nov 24, 2023 · Editas Medicine Stock Forecast 11-26-2023. Forecast target price for 11-26-2023: $ 10.97. Positive dynamics for Editas Medicine shares will prevail with possible volatility of 3.528%. Pessimistic target level: 10.80. Optimistic target level: 11.19. Editas Medicine Stock Forecast and Price Target. Based on the current earnings figures, this year's price targets for Editas Medicine were recently set by distinguished experts, with an average mark of $12.00. If it reached this goal, it would represent a potential upside of approximately 11.42% from the previous closing price in December, 2023.Editas Medicine Stock Forecast. ... According to 12 stock analysts, the average 12-month stock price forecast for EDIT stock stock is $14.17, which predicts an ...

Current Price. $10.46. Price as of November 22, 2023, 11:14 a.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 46.41% so far this month. During the month of November, Editas Medicine Inc’s stock price has reached a high of $9.83 and a low of $6.66. Over the last year, Editas Medicine Inc has hit prices as high as $11.93 and as low as $6.08. Year to date, Editas ...Price of Stock Editas Medicine (EDIT) Today.

The average price targets for Editas Medicine and Intellia Therapeutics are $13.18 and $83.75, respectively, according to Yahoo! Finance. That implies an upside of about 54% for the former and 119 ...

CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses.--Editas Medicine, Inc., a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per ...The current Editas Medicine [ EDIT] share price is $9.78. The Score for EDIT is 55, which is 10% above its historic median score of 50, and infers lower risk than normal. EDIT is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to …Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.

Sep 29, 2023 · Stifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17. ... Shares of Editas Medicine (EDIT 2.28%) ...

CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and …

Editas Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. Nov. 03. CI. North American Morning Briefing : S&P 500 Futures -2-. Nov. 03. DJ. Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored ... The Motley Fool has positions in and recommends Beam Therapeutics, CRISPR Therapeutics, Caribou Biosciences, Editas Medicine, Intellia Therapeutics, and Vertex …Historical daily share price chart and data for Editas Medicine since 2016 adjusted for splits and dividends. The latest closing stock price for Editas Medicine as of November 20, …Shares of Editas Medicine (EDIT 3.66%) ... which have yet to be adequately reflected in stock prices. Of course, the flip side is that the merger doesn't make as much sense for Beam Therapeutics. ...Conference Call. The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial results for the third quarter of 2023. To access the call, please dial 1-877-407-0989 (domestic) or 1-201-389-0921 (international) and ask for the Editas …Jun 6, 2021 · For Editas Medicine stock forecast for 2031, 12 predictions are offered for each month of 2031 with average Editas Medicine stock forecast of $8.2, a high forecast of $8.21, and a low forecast of $8.19. The average Editas Medicine stock forecast 2031 represents a 4.21% increase from the last price of $7.86999988555908. Stifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17. The upgrade reflects optimism about Editas' progress in developing a gene-editing therapy ...

The Editas Medicine management team will host a conference call and webcast today at 8:00 a.m. ET to provide and discuss a corporate update and financial results for the second quarter of 2023. To access the call, please dial 1-877-407-0989 (domestic) or 1-201-389-0921 (international) and ask for the Editas Medicine earnings call.Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geulah Livshits from Chardan Capital remains neutral on the stock ...Feb 2, 2023 · Why Editas Medicine Stock Charged Higher in January. By George Budwell – Feb 2, 2023 at 11:33AM Key Points. ... Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET. Consider, for instance, Editas Medicine (EDIT-6.20%) ... Stock Advisor list price is $199 per year. Join Stock Advisor Cumulative Growth of a $10,000 Investment in Stock Advisor.Another Jennifer Doudna co-founded company is Editas Medicine (NASDAQ: EDIT). Like Intellia, Editas is among the gene editing stocks using CRISPR/Cas9 systems to to solve incurable diseases.Editas Medicine Inc () Stock Market info Recommendations: Buy or sell Editas Medicine stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Editas Medicine share forecasts, stock quote and buy / sell signals below.According to present data Editas Medicine's EDIT shares and potentially its market environment …

Our indicative theme on Gene Editing Stocks - which includes names such as CRISPR Therapeutics, Editas Medicine, and others - has returned about 230% over the past 2 years, compared to the broader ...Nov 30, 2023 · A high-level overview of Editas Medicine, Inc. (EDIT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Editas Medicine Inc () Stock Market info Recommendations: Buy or sell Editas Medicine stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Editas Medicine share forecasts, stock quote and buy / sell signals below.According to present data Editas Medicine's EDIT shares and potentially its market environment …Stock price history for Editas Medicine (EDIT). Highest end of day price: $90.58 USD on 2021-01-08. Lowest end of day price: $6.36 USD on 2023-04-12. Stock ...View live Editas Medicine, Inc. chart to track its stock's price action. Find market predictions, EDIT financials and market news.Stock Quote. Change Volume 52 Week High 52 Week Low Dec 2, 2023 5:42 PM EST. Data Provided by Refinitiv. Minimum 15 minutes delayed. Upcoming Events EDIT-301 Program Update: RUBY and EdiTHAL Trials Data Update, December 2023. ... Editas Medicine, Inc. Phone: 617.401.0113 E-mail: [email protected] >> Main …Another Jennifer Doudna co-founded company is Editas Medicine (NASDAQ: EDIT). Like Intellia, Editas is among the gene editing stocks using CRISPR/Cas9 systems to to solve incurable diseases.Editas Medicine stock price prediction is an act of determining the future value of Editas Medicine shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Editas Medicine's future price could yield a significant profit.Nov 2, 2023 · Editas Medicine releases earnings for the most recent quarter on November 3. Analysts predict Editas Medicine will release losses per share of $0.575. Go here to track Editas Medicine stock price ... Stock Quote. Change Volume 52 Week High 52 Week Low Dec 2, 2023 5:42 PM EST. Data Provided by Refinitiv. Minimum 15 minutes delayed. Upcoming Events EDIT-301 Program Update: RUBY and EdiTHAL Trials Data Update, December 2023. ... Editas Medicine, Inc. Phone: 617.401.0113 E-mail: [email protected] >> Main …

Get the LIVE share price of Editas Medicine Inc(EDIT) and stock performance in one place to strengthen your trading strategy in US stocks. Now Start Investing in Editas Medicine Inc on Groww. Editas Medicine Inc. Healthcare. $10.77 +0.24(2.28%) 1D. 1D. 1W. 1M. 1Y. 3Y. 5Y. Performance. Open Price: Prev. Close: Volume: Avg. Volume: …

Nov 24, 2023 · What is the target price for Editas Medicine (EDIT) stock? A. The latest price target for . Editas Medicine (NASDAQ: EDIT) was reported by Citigroup on Tuesday, October 24, 2023.

What was the 52-week low for Editas Medicine stock? The low in the last 52 weeks of Editas Medicine stock was 6.08. According to the current price, Editas Medicine is 174.67% away from the 52-week ... Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.Editas Medicine, Inc. Common Stock (EDIT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Insider Monkey’s database tracked Editas Medicine, Inc. (NASDAQ:EDIT) in 8 billionaire portfolios at the end of March. It is one of the top DNA stocks to monitor.Apr 17, 2023 · Shares of clinical-stage biotech Editas Medicine ( EDIT 3.66%) rose as much as 14% on Monday, lifted by a trend over the past couple of days favoring gene-editing stocks. Editas stock also ... Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 62.28% so far this month. During the month of November, Editas Medicine Inc’s stock price has reached a high of $11.14 and a low of $6.66. Over the last year, Editas Medicine Inc has hit prices as high as $11.93 and as low as $6.08. Year to date, Editas ...Another Jennifer Doudna co-founded company is Editas Medicine (NASDAQ: EDIT). Like Intellia, Editas is among the gene editing stocks using CRISPR/Cas9 systems to to solve incurable diseases.Jun 6, 2021 · For Editas Medicine stock forecast for 2031, 12 predictions are offered for each month of 2031 with average Editas Medicine stock forecast of $8.2, a high forecast of $8.21, and a low forecast of $8.19. The average Editas Medicine stock forecast 2031 represents a 4.21% increase from the last price of $7.86999988555908.

Editas Medicine. Market Cap. $860M. Today's Change. (-0.75%) -$0.08. Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may ...Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Complete Editas Medicine Inc. stock information by Barron's. View real-time EDIT stock price and news, along with industry-best analysis.Instagram:https://instagram. nasdaq adbe compareland stockscommercial real estate stockshow to buy stocks with a credit card Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street. commercial real estate stockmedtronic share price Dec 1, 2023 · Editas Medicine Stock Forecast. ... According to 12 stock analysts, the average 12-month stock price forecast for EDIT stock stock is $14.17, which predicts an ... View the latest Editas Medicine Inc. (EDIT) stock price, news, historical charts, analyst ratings and financial information from WSJ. bank of america bond EDIT Editas Medicine Inc. 10.57 -0.15 ( -1.40%) Market Closed Delayed Prices By NASDAQ, in USD. Trade. Overview Chart Analysis News Stats.The stock bounced back a bit toward the end of the day but was still down as much as 13.8% by 2 p.m. EST. Editas has a 52-week low of $9.59 and a 52-week high of $37.50, and is down more than 60% ...View Editas Medicine, Inc EDIT investment & stock information. Get the latest Editas Medicine, Inc EDIT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.